A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects

NCT03776240 | Completed Phase 1 DMC

• 1 other identifier: TROIKA-1
• Study Type: interventional
• Target: 105
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to demonstrate demonstrate the pharmacokinetic (PK) similarity of HD201 to the European (EU) and American (US) reference products Herceptin, following a single i.v. infusion of 6 mg/kg in healthy volunteers.

Conditions

Healthy Volunteers

Keywords

randomized; double-blind

Outcome Measures

Primary Outcomes (1)

• Area under Curve (AUC, Pharmacokinetics)

  Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin

  Up to day 54

Secondary Outcomes (1)

• Immunogenicity: Incidence of anti-herceptin antibodies

  0 hour, Day 15, Day 29, Day 43, and Day 54 post-dose

Study Arms (3)

HD201

EXPERIMENTAL

Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Drug: HD201

EU-licensed Herceptin

ACTIVE COMPARATOR

Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Drug: EU-Herceptin

US-licensed Herceptin

ACTIVE COMPARATOR

Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Drug: US-Herceptin

Interventions

HD201 DRUG

Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Also known as: Trastuzumab

HD201

EU-Herceptin DRUG

Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Also known as: Trastuzumab

EU-licensed Herceptin

US-Herceptin DRUG

Single-dose 6mg/kg body weight by 90 minute intravenous infusion

Also known as: Trastuzumab

US-licensed Herceptin

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male, non-smoker (no use of tobacco products within 3 months prior to screening), ≥ 18 and ≤ 55 years of age, with BMI \> 18.5 and \< 30.0 kg/m2 and body weight ≥ 50.0 kg.
• Healthy as defined by:
• the absence of clinically significant history of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
• a LVEF within the normal range as measured by echocardiogram (ECHO) within 4 weeks prior to randomization.
• the absence of clinically significant history of anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
• Male subjects who are not vasectomized for at least 6 months, and who are sexually active with non-sterile female partner \[sterile female partners include post-menopausal women (absence of menses for 12 months prior to drug administration) or women who have had a tubal ligation, hysterectomy, or bilateral oophorectomy (at least 6 months prior to drug administration)\] must be willing to use one of the following acceptable contraceptive method throughout the study and for 90 days after the last study drug administration:
• simultaneous use of condom, and for the female partner hormonal contraceptives (used since at least 4 weeks) or intra-uterine contraceptive device (placed since at least 4 weeks);
• simultaneous use of male condom, and for the female partner, diaphragm with intravaginally applied spermicide.
• Male subjects, including men who have had vasectomy, with a pregnant partner must agree to use a condom throughout the study and for 90 days after the last study drug administration.
• Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
• Capable of consent.

You may not qualify if:

• f the following applies will be excluded from the study:
• Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
• Positive urine drug screen at screening.
• History of allergic reactions to trastuzumab, benzyl alcohol, murine proteins, or other related drugs.
• Any reason which, in the opinion of the Principal Investigator, would prevent the subject from participating in the study.
• Clinically significant ECG abnormalities (QTc \>450 ms) and or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
• History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week \[1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol\]).
• History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
• Previous use of trastuzumab or another monoclonal antibody for a medical condition or in the context of another clinical trial.
• Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
• Use of medication other than topical products without significant systemic absorption:
• prescription medication within 14 days prior to dose administration;
• over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to dosing, with the exception of the occasional use of acetaminophen (paracetamol - up to 2 g daily);
• a depot injection or an implant of any drug within 3 months prior to dose administration.
• Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.

Sponsors & Collaborators

• Prestige Biopharma Limited: lead

Study Sites (1)

Q Pharm

Brisbane, Australia

Location

Related Publications (1)

• Demarchi M, Coliat P, Mclendon K, Chung Shii Hii J, Feyaerts P, Ang F, Jaison L, Deforce F, Derde MP, Kim MJ, Park LS, Detappe A, Pivot X. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin(R) and US-Herceptin(R) in healthy male subjects. Pharmacol Res Perspect. 2021 Aug;9(4):e00839. doi: 10.1002/prp2.839.

  PMID: 34309241 DERIVED

MeSH Terms

Interventions

Trastuzumab

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: SCREENING
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 13, 2018
• First Posted: December 14, 2018
• Study Start: April 1, 2019
• Primary Completion: August 19, 2019
• Study Completion: August 19, 2019
• Last Updated: November 19, 2024

Record last verified: 2023-02

Locations

AU (1)